Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026)
Denali Therapeutics (DNLI) reported Enterprise Value of -$987.7 million for Q1 2026, down 20.75% year-over-year from -$1.2 billion in Q1 2025, and down 13.8% on a QoQ basis from -$867.9 million in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Enterprise Value data on file, last reported at -$987.7 million in Q1 2026.
- Quarterly Enterprise Value fell 20.75% year-over-year to -$987.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$987.7 million (down 20.75% YoY) and the FY2025 annual result came in at -$867.9 million, down 4.27% from the prior year.
- Enterprise Value retreated to -$987.7 million in Q1 2026 per DNLI's latest filing, from -$867.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$817.9 million in Q1 2025 and bottomed at -$1.3 billion in Q4 2022.
- The 5-year median for Enterprise Value is -$957.5 million (2022), against an average of -$1.0 billion.
- Peak annual rise in Enterprise Value reached 32.24% in 2022, while the deepest fall reached 54.4% in 2022.
- Tracing DNLI's Enterprise Value over 5 years: stood at -$1.3 billion in 2022, then grew by 22.58% to -$1.0 billion in 2023, then climbed by 19.54% to -$832.3 million in 2024, then retreated by 4.27% to -$867.9 million in 2025, then decreased by 13.8% to -$987.7 million in 2026.
- Per Business Quant, the three latest DNLI Enterprise Value figures stand at -$987.7 million (Q1 2026), -$867.9 million (Q4 2025), and -$848.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -987.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -987.68 Mn |
| Dec 31, 2025 | -867.88 Mn |
| Sep 30, 2025 | -848.20 Mn |
| Jun 30, 2025 | -898.95 Mn |
| Mar 31, 2025 | -817.93 Mn |
| Dec 31, 2024 | -832.33 Mn |
| Sep 30, 2024 | -836.56 Mn |
| Jun 30, 2024 | -896.04 Mn |
| Mar 31, 2024 | -936.87 Mn |
| Dec 31, 2023 | -1.03 Bn |
| Sep 30, 2023 | -1.11 Bn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -1.29 Bn |
| Dec 31, 2022 | -1.34 Bn |
| Sep 30, 2022 | -1.11 Bn |
| Jun 30, 2022 | -1.07 Bn |
| Mar 31, 2022 | -957.52 Mn |
| Dec 31, 2021 | -865.41 Mn |
| Sep 30, 2021 | -1.04 Bn |
| Jun 30, 2021 | -1.31 Bn |
| Mar 31, 2021 | -1.41 Bn |
| Dec 31, 2020 | -1.47 Bn |
| Sep 30, 2020 | -961.20 Mn |
| Jun 30, 2020 | -549.58 Mn |
| Mar 31, 2020 | -587.25 Mn |
| Dec 31, 2019 | -415.36 Mn |
| Sep 30, 2019 | -479.39 Mn |
| Jun 30, 2019 | -478.60 Mn |
| Mar 31, 2019 | -485.48 Mn |
| Dec 31, 2018 | -464.30 Mn |
| Sep 30, 2018 | -374.96 Mn |
| Jun 30, 2018 | -372.59 Mn |
| Mar 31, 2018 | -373.40 Mn |
| Dec 31, 2017 | -406.23 Mn |
| Sep 30, 2017 | -36.27 Mn |
| Jun 30, 2017 | -41.31 Mn |
| Mar 31, 2017 | -36.75 Mn |